Cardio-Oncology

The European Society of Cardiology task force on cardio-oncology has issued its inaugural guideline for the prevention and management of cardiotoxicity before, during and after adult patients are treated with anticancer therapies.

Patients who received the chemotherapy drug doxorubicin for childhood cancer and harbor a specific genetic mutation near the KCNK17 gene experienced significantly greater risk for heart disease later in life, study results have shown.

Rates for CV admissions among patients with cancer has increased, according to a study published in the European Heart Journal Quality of Care & Clinical Outcomes.Primary CV admissions are highest among patients with hematological cancer with the most common cause of admission being heart failure, according to the study.

A growing body of evidence suggests cancer survivors face elevated risk for cardiovascular disease years after diagnosis.

Men, older patients and patients with low income were among those with elevated risk for CVD hospitalization prior to receiving a diagnosis of potentially curable cancer, researchers reported.

The U.S. Preventive Services Task Force issued a recommendation statement against the use of beta carotene or vitamin E supplements for the prevention of CVD or cancer.

In patients with diabetes and cancer treated with anthracyclines, SGLT2 inhibition was associated with fewer cardiac events during 1.5 years of follow-up, researchers reported.

CHICAGO — Patients and prescribers should be more aware of the potential for major adverse cardiac events after immune checkpoint inhibitor-based therapy, according to retrospective study results presented at ASCO Annual Meeting.

Older women with overweight who received cardiotoxic treatment for breast cancer saw a 15% relative CVD risk reduction after following an 8-week time-restricted eating plan, according to research published in JACC: CardioOncology.

Healio and Cardiology Today have compiled a list of the top read news in cardiology of March 2022.